Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Sangamo Therapeutics (SGMO) EBIAT (2016 - 2025)

Sangamo Therapeutics has reported EBIAT over the past 16 years, most recently at -$37.4 million for Q4 2025.

  • Quarterly results put EBIAT at -$37.4 million for Q4 2025, down 59.94% from a year ago — trailing twelve months through Dec 2025 was -$122.9 million (down 25.52% YoY), and the annual figure for FY2025 was -$122.9 million, down 25.52%.
  • EBIAT for Q4 2025 was -$37.4 million at Sangamo Therapeutics, down from -$34.9 million in the prior quarter.
  • Over the last five years, EBIAT for SGMO hit a ceiling of $21.1 million in Q1 2023 and a floor of -$114.5 million in Q2 2023.
  • Median EBIAT over the past 5 years was -$43.6 million (2022), compared with a mean of -$42.5 million.
  • Biggest five-year swings in EBIAT: tumbled 3062.33% in 2021 and later surged 148.05% in 2023.
  • Sangamo Therapeutics' EBIAT stood at -$37.5 million in 2021, then plummeted by 38.61% to -$52.0 million in 2022, then dropped by 16.01% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 59.94% to -$37.4 million in 2025.
  • The last three reported values for EBIAT were -$37.4 million (Q4 2025), -$34.9 million (Q3 2025), and -$20.0 million (Q2 2025) per Business Quant data.